Latest Conference Articles

February 14th 2013, 8:29am

Genitourinary Cancers Symposium (ASCO GU)

Shortening the course of androgen blockade therapy from 36 months to 18 months when combined with radiation therapy does not appear to compromise outcomes in patients with high-risk prostate cancer

February 14th 2013, 6:48am

Genitourinary Cancers Symposium (ASCO GU)

A large, retrospective study has found that high-risk prostate cancer that can only be detected through PSA testing is more likely to occur among men over the age of 75 and in African Americans.

February 12th 2013, 7:09am

ASH Annual Meeting and Exposition

Francesco Lo-Coco, MD, Hematology, University Tor Vergata, discusses a new emerging treatment, arsenic trioxide, in acute promyelocytic leukemia.

January 28th 2013, 5:33pm

Gastrointestinal Cancers Symposium (ASCO GI)

Ghassan K. Abou-Alfa, MD, from Memorial Sloan-Kettering Cancer Center, discusses a study that examined the utility of doxorubicin-eluting beads in hepatic arterial embolization as a treatment for hepatocellular carcinoma.

January 28th 2013, 2:16pm

Gastrointestinal Cancers Symposium (ASCO GI)

The 2013 Gastrointestinal Cancers Symposium was held at the Moscone West Building, San Francisco, CA, from January 24-26.

January 28th 2013, 10:45am

Gastrointestinal Cancers Symposium (ASCO GI)

Adding nab-paclitaxel to gemcitabine improves survival compared with gemcitabine alone in patients with metastatic pancreatic cancer.

January 28th 2013, 10:10am

Gastrointestinal Cancers Symposium (ASCO GI)

Ramucirumab significantly extended overall survival as a second-line agent in patients with metastatic gastric or gastroesophageal junction adenocarcinoma that progressed on first-line therapy.

January 28th 2013, 9:56am

Gastrointestinal Cancers Symposium (ASCO GI)

Patients with metastatic colorectal cancer whose disease had progressed despite treatment with oxaliplatin experienced an improvement in survival by switching to a regimen of ziv-aflibercept plus FOLFIRI.

January 28th 2013, 9:01am

Gastrointestinal Cancers Symposium (ASCO GI)

Axel Grothey, MD, from the Mayo Clinic, Rochester, Minnesota, discusses the time course of adverse events following treatment with regorafenib, as observed in the CORRECT study.

January 25th 2013, 3:25pm

Gastrointestinal Cancers Symposium (ASCO GI)

Adjuvant chemotherapy with the oral fluoropyrimidine S-1 improved survival versus standard postoperative gemcitabine in Asian patients with pancreatic cancer, according to an interim analysis from a phase III trial conducted in Japan.

January 25th 2013, 1:10pm

Gastrointestinal Cancers Symposium (ASCO GI)

Ramesh K. Ramanathan, MD, from the Virginia G. Piper Cancer Center, discusses the phase III MPACT study that examined gemcitabine plus nab-paclitaxel in patients with metastatic adenocarcinoma of the pancreas.

January 25th 2013, 1:09pm

Gastrointestinal Cancers Symposium (ASCO GI)

William M. Grady, MD, from the Fred Hutchinson Cancer Research Center, discusses results from a study that examined the association of intrinsic subtypes of colorectal cancer with prognosis, chemotherapy response, and other factors.

January 25th 2013, 7:15am

Gastrointestinal Cancers Symposium (ASCO GI)

A simple blood draw could lead to life-prolonging adjustments in treatment for patients with pancreatic cancer, the authors of a study have found.

January 24th 2013, 8:31am

Gastrointestinal Cancers Symposium (ASCO GI)

Using a new classification system that categorizes colorectal cancers by tumor gene expression patterns, researchers have determined that tumor prognosis and response to adjuvant chemotherapy in CRC vary according to molecular subtype.

January 23rd 2013, 1:51pm

Gastrointestinal Cancers Symposium (ASCO GI)

Patients with advanced esophagogastric adenocarcinoma who received docetaxel as a second-line therapy experienced a longer period of overall survival as well as a better quality of life compared with patients who received active symptom control.

January 23rd 2013, 1:31pm

Gastrointestinal Cancers Symposium (ASCO GI)

A retrospective analysis of the potential benefits of surgery following treatment with imatinib (Gleevec) suggests a clear benefit in both OS and PFS in patients with metastatic or recurrent GIST when compared with those who received imatinib therapy alone.

December 11th 2012, 3:08pm

ASH Annual Meeting and Exposition

Andrew D. Zelenetz, MD, PhD, from Memorial Sloan-Kettering Cancer Center, discusses the trials investigating ABT-199 and ibrutinib that were presented at the 2012 American Society of Hematology (ASH) Meeting.

December 11th 2012, 1:44pm

ASH Annual Meeting and Exposition

Proposed federal budget cuts that could affect the National Institutes of Health, and thus hematology/oncology research, were highlighted as an area of concern during the 54th Annual Meeting of the American Society of Hematology in Atlanta, Georgia.

December 11th 2012, 1:24pm

ASH Annual Meeting and Exposition

Photos from the 54th American Society of Hematology (ASH) Annual Meeting and Exposition, held at the Georgia World Congress Center, Atlanta, GA, from December 8-11, 2012.

December 10th 2012, 2:16pm

San Antonio Breast Cancer Symposium

Carlos L. Arteaga, MD, from Vanderbilt-Ingram Cancer Center, describes key takeaway points for practicing oncologists, clinical investigators, and scientists from the 2012 SABCS.